Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1992 Feb;22(2):132-43.
doi: 10.2165/00003088-199222020-00004.

Considerations in dosage selection for third generation cephalosporins

Affiliations
Review

Considerations in dosage selection for third generation cephalosporins

J H Yuk-Choi et al. Clin Pharmacokinet. 1992 Feb.

Abstract

Pharmacokinetic parameters of third generation cephalosporins vary widely, requiring different dosage regimens and adjustment methods for each agent. Although their antibacterial spectrum favours their usage in infections caused by aerobic Gram-negative organisms, due to their limited post-antibiotic effect against these organisms, dosage regimens should ensure that free drug concentrations at the site of infection remain above the minimum inhibitory concentration for as much of the dosage interval as possible in patients with normal host defence mechanisms and for the entire dosage interval in immunocompromised patients. Altered protein binding encountered in various disease states can affect both microbiological and pharmacokinetic properties especially for drugs with high protein binding. Since the concentrations at the site of action are often different from those in serum, a higher or lower range of dosages needs to be selected depending on the target site. Decreased renal function affects the elimination of most third generation cephalosporins, whereas the presence of hepatic disease does not generally necessitate dosage adjustment. Because of the complex age-related physiological changes in paediatric and elderly patients, dosage should be adjusted on the basis of the reported pharmacokinetic data in these populations. The usual recommended dose may or may not be optimal in a given condition depending on the complex interactions between pharmacokinetic, microbiological and other host factors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Rev Infect Dis. 1983 Mar-Apr;5 Suppl 1:S127-36 - PubMed
    1. Clin Pharmacokinet. 1989 Oct;17(4):223-35 - PubMed
    1. Antimicrob Agents Chemother. 1990 Apr;34(4):519-23 - PubMed
    1. Antimicrob Agents Chemother. 1984 Sep;26(3):347-50 - PubMed
    1. Int J Clin Pharmacol Res. 1986;6(2):171-5 - PubMed

MeSH terms

LinkOut - more resources